Welcome to our dedicated page for Kemper SEC filings (Ticker: KMPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kemper’s statutory reserve tables, reinsurance schedules, and actuarial assumptions can push a single 10-K well past 300 pages. If you are searching for the latest loss-ratio trend or wondering how recent catastrophe claims affect capital, line-by-line scrolling wastes time. Many visitors ask, “Where can I find the Kemper quarterly earnings report 10-Q filing?” or “How do I monitor Kemper insider trading Form 4 transactions?” Stock Titan delivers every disclosure the moment EDGAR posts, giving you Kemper SEC filings explained simply before the market reacts.
Open any document—annual report 10-K, 8-K event notice, or proxy statement—and our AI-powered summaries translate dense insurance language into plain English. Need Kemper proxy statement executive compensation details? The platform flags pay-for-performance tables instantly. Want Kemper Form 4 insider transactions real-time? Receive alerts the second directors buy or sell. Get the Kemper annual report 10-K simplified into a concise brief, and access a full Kemper earnings report filing analysis that highlights policy acquisition costs, reserve changes, and segment profitability without combing through footnotes.
Because Kemper underwrites both Specialty Property & Casualty and Life policies, different risks surface across forms. Stock Titan links each filing type to what matters: Kemper 8-K material events explained around catastrophe losses, Schedule 13D shifts that flag activist interest, and reinsurance-ceded data mapped across divisions. Use interactive tools to compare combined ratios over time or track executive stock transactions Form 4 alongside reserve releases. Understanding Kemper SEC documents with AI moves you from data to decision in minutes, with comprehensive, continuously updated access to every filing.
Arteris, Inc. (AIP) – Form 144 filing
An affiliated insider has filed to sell up to 50,000 common shares on or after 05 Aug 2025 through Morgan Stanley Smith Barney. The notice values the block at about $472,500, implying a reference price of roughly $9.45 per share. With 41.98 million shares outstanding, the proposed sale represents only ~0.12 % of outstanding stock, suggesting minimal direct market impact.
The shares were originally acquired on 05 Nov 2013 via a private transaction with the issuer. Recent Rule 10b5-1 activity shows the same filer sold 40,254 shares between 27 Jun and 03 Jul 2025 for aggregate proceeds of about $384 k. A Form 144 is a notice of intent—execution is not guaranteed—but it extends a pattern of insider monetisation. While the size is modest, continued sales can create a slight supply overhang; conversely, use of a pre-arranged trading plan points to routine diversification rather than a negative signal on fundamentals.
The Form 144 filing shows a Gevo, Inc. (GEVO) shareholder intends to sell up to 28,500 common shares through Stifel Nicolaus on Nasdaq. The block equals roughly 0.01 % of the 239,562,995 shares outstanding and carries an aggregate market value of $35,072, implying a reference price near $1.23 per share. The proposed sale date is 08/05/2025.
The shares were acquired on 08/03/2025 via restricted stock units and will be paid for in cash at settlement. The same seller, Kimberly Bowron, disposed of 35,688 shares during the prior three months for gross proceeds of $45,411. No material adverse information is asserted in the notice, and no additional company financial data are provided.
Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) filed an 8-K disclosing its ninth one-month extension to complete a business combination. The Board moved the deadline, known as the “Business Combination Period,” from 5 Aug 2025 to 5 Sep 2025.
To effect the extension, sponsor CGC II Sponsor LLC will advance $250,000 under an unsecured promissory note that permits borrowings up to $2.4 million. The funds will be deposited into the IPO trust account as required by the company’s amended memorandum and articles.
This is the 9th of 12 permissible monthly extensions; no additional financial results, target identification, or other material transactions were reported.
FAQ
What is the current stock price of Kemper (KMPR)?
What is the market cap of Kemper (KMPR)?
What core services does Kemper Corp provide?
How is Kemper Corp structured in terms of its business segments?
How does Kemper generate revenue?
What role does the independent agent network play for Kemper?
How does Kemper maintain its underwriting standards?
What distinguishes Kemper's insurance offerings from its competitors?
How is Kemper positioned within the insurance industry?
Can you explain Kemper's approach to risk management?
